ORTEXORTEX News
Tracking RNR? Get live short interest, options flow, and signals on ORTEX.Sign up free →
RN
Earnings PreviewRNR

RNR's Defensive Options Bet Has Grown — and the Print Is Now Here

By ORTEX News · Edited by , Editor, ORTEX News2 min readdata as of 23 Jul 2026, 04:10

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

RenaissanceRe heads into today's Q2 earnings report with options positioning even more defensively skewed than when the first alarm was raised four days ago.

The put/call ratio has climbed further to 0.64 — more than two standard deviations above its 20-day average of 0.36, a z-score of 2.27. That reading is lower than the 3.15 spike flagged on July 17, but the sustained elevation over three consecutive sessions tells a more durable story: this is not a single-day noise event. Investors have been paying for downside protection through the week. The stock gave back a small amount on Tuesday, slipping 0.5% to $319.69, even as the one-week gain held at nearly 4% and the one-month advance remained close to 7%. Peers were mixed — CB fell 3.3% on the day while TRV added 0.7% — so the options skew looks idiosyncratic to the RNR print rather than a sector-wide rotation.

The lending market, by contrast, signals no meaningful bearish conviction. Borrow availability is extraordinarily loose at roughly 2,950% — meaning nearly 30 shares are available for every one currently on loan — and short interest has eased almost 10% over the past month to 3.3% of the free float. Cost to borrow ticked up 25% on the week but remains negligible at 0.50%. The gap between the nervous options market and the relaxed lending market is the central tension heading into the print.

Analysts have spent the past two weeks lifting targets with little conviction behind the moves. JP Morgan raised its target to $360 on Monday — the most bullish individual call — but kept a Neutral rating. The broader wave of target increases across Morgan Stanley, UBS, Barclays, Wells Fargo and others through early July followed the same pattern: higher numbers, unchanged ratings. The consensus mean of $339 sits only modestly above the current price of $319.69. Bulls point to 8% catastrophe premium growth led by a 13% surge in U.S. business and the expectation that core loss ratios improve year-over-year. Bears flag soft pricing in key lines as a ceiling on multiple expansion, with EPS estimates sensitive enough that small misses carry outsized price-target implications.

Past prints have not been kind — the last two earnings events each produced a 1-2% day-one decline and a roughly 2.5-3% five-day drift lower. Today's report will test whether the June momentum, a wave of analyst target upgrades, and a recovering stock price can survive contact with actual Q2 numbers on catastrophe losses, pricing trends, and reserve development.

Stocks in this article

See the live data behind this article on ORTEX.

Open RNR on ORTEX →

How this article was generated

Generated
23 Jul 2026, 04:14
Data as of
23 Jul 2026, 04:10
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.